Journey Medical Corporation

DERM Healthcare Drug Manufacturers Specialty & Generic

Journey Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $61.9 million, up 10.2% from fiscal 2024. In the quarter to June 2026, revenue grew 23.3%, EPS grew 93.8%, free cash flow fell 84.1% and total debt rose 1.43%, each against the same quarter a year earlier.

4.97 0.16 −3.12%
Market cap
$144.7M
P/E
0.0×
Fwd P/E
91.8×
Dividend yield
—
F-score
4/9
Altman Z
1.09
Beneish M
−0.82
Dividend safety
n/a
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — 3 3 7 2 4
P/E ratio
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
— — — (0.09) (0.72) 0.97 (0.39) 1.09
P/S ratio
— 1.65 1.65 0.87 0.44 1.25 1.42 3.05
P/FCF ratio
— 14.92 14.92 0.00 0.00 412.50 0.00 0.00
Altman Z″-Score (non-manufacturers)
— 1.97 2.51 (0.70) (3.00) (1.63) (3.27) (1.40)
Beneish M-Score
— — (2.14) (4.23) (3.28) (3.43) (3.10) (0.82)
P/Operating CF
— 12.77 12.77 (17.10) (8.41) (5.99) 35.90 (30.06)
P/B ratio
— 0.00 0.00 1.30 1.90 4.86 3.98 5.93
EV/Sales
— 1.61 1.61 0.16 0.31 1.13 1.56 3.16
EV/EBITDA
— 0.00 0.00 0.00 0.00 17.19 0.00 0.00
EV/FCF
— 14.56 14.56 (0.77) (0.69) 372.00 (3.63) (7.13)
Current Ratio
— 1.21 1.26 1.64 1.16 1.35 1.37 1.79
Net Debt/EBITDA
— 0.08 0.17 1.50 0.40 (2.47) (0.46) (0.35)
Debt/Equity
— 1.93 0.95 0.11 1.34 0.72 1.24 0.79
ROE
— 55.58% 81.00% (168.12%) (100.39%) (20.64%) (72.60%) (44.03%)
ROA
— 21.41% 12.32% (58.98%) (29.27%) (4.23%) (18.68%) (13.08%)
ROIC
— 101.01% 41.33% 0.00% (221.83%) (17.20%) (34.69%) (15.46%)
Return on Tangible Assets
— 82.84% 73.57% (133.81%) (273.14%) (26.41%) (112.83%) (38.84%)
Average Days of Receivables
— 198.12 196.13 133.62 139.76 70.17 66.53 175.74
Earnings Yield
— (24.52%) (24.52%) (75.66%) (91.30%) (4.42%) (18.93%) (6.10%)
Free Cash Flow Yield
— 6.70% 6.70% (24.04%) (103.96%) 0.24% (30.20%) (14.53%)
Free Cash Flow per Share
— 0.72 0.43 (1.20) (1.91) 0.01 (1.18) (0.51)
Book value per Share
— 0.30 1.13 4.13 0.97 1.12 0.98 1.30
Free Cash Flow
— 6.62 3.93 (12.18) (33.53) 0.24 (24.13) (12.44)
EV/EBIT
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates